K2 Therapeutics CEO discusses China's biotech rise, the case for global asset acquisition, and what defines a successful biotech.
Ying Huang, PhD
Advertisement
Ying Huang, Ph.D., is the Chief Executive Officer and Board Director of K2 Therapeutics, and Strategic Advisor, APAC at MPM BioImpact. He brings over 9 years of experience in research and development at a major pharmaceutical company and 12 years of experience as a biotechnology analyst on Wall Street.
Articles by Ying Huang, PhD
K2 Therapeutics CEO Ying Huang discusses the three priorities that define a successful biotech: unmet need, development cost, and accessible pricing.
K2 Therapeutics CEO Ying Huang on the drug development pipeline — and the compounding attrition rates that make FDA approval the exception.
K2 Therapeutics CEO Ying Huang on how in-licensing assets with existing human data can cut years and billions from the drug development timeline.
K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech innovation surge irreversible.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Agentic AI Revolution in Biopharma
2
Artisan Partners’ Director Calls for Novartis Board Shake-Up
3
340B Under Pressure: Inside Pharma's Push for Greater Clarity
4
Pharmaceutical Executive Daily: David Samra Calls For Novartis Board Shake-Up
5